During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and ...

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

An AI system called iSeg is reshaping radiation oncology by automatically outlining lung tumors in 3D as they shift with each ...

When non-small cell lung cancer (NSCLC) spreads beyond the lungs, it often metastasizes to the bones. Estimates suggest 20 to 30 percent of people with NSCLC have bone metastases at the time of ...

The collaboration aims to evaluate the combination across three priority tumor types, including RAS mutant non-small cell lung cancer, pancreatic ductal adenocarcinoma and colorectal cancer.

DNMT3A mutations emerged as potential biomarkers for enhanced immunotherapy benefit in non-small cell lung cancer.

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...

A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...

Elevated NLR may no longer predict poor survival outcomes in patients with small cell lung cancer (SCLC) receiving ...